IBRX Q2 2022 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$35,000-89.7% YoY

Gross Profit

-$6M-16845.7% margin

Operating Income

-$80M-227491.4% margin

Net Income

-$95M-270251.4% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

+150.0%

Cash Flow

Operating Cash Flow

-$91M

Free Cash Flow

-$107M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$318M

Total Liabilities

$740M

Stockholders' Equity

-$420M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$35,000	$339,000	-89.7%
Gross Profit	-$6M	$339,000	-1839.2%
Operating Income	-$80M	-$86M	+7.3%
Net Income	-$95M	-$88M	-7.1%